Guoxing Xu

966 citations
28 papers · 481 indexed · h-index 11
Topics
Pluripotent Stem Cells Research (5 papers)Cancer Cells and Metastasis (3 papers)CRISPR and Genetic Engineering (3 papers)

In The Last Decade

Guoxing Xu

28 papers receiving 478 citations

Peers

Guoxing Xu
Comparison fields: 5 of 66
  • Molecular Biology 304
  • Surgery 153
  • Oncology 76
  • Cancer Research 76
  • Cellular and Molecular Neuroscience 60
Replace Jung‐Sun Cho with:
Jung‐Sun Cho South Korea
Ahmed Ibrahim United States
Shelly Zaffryar‐Eilot Israel
И. Б. Белоглазова Russia
Belén Prados Spain
Xueping Gu China
Xiuli Zhao China
April M. Craft United States
Dongjin Wu China
Matt Weaver United States
Guoxing Xu relative to Jung‐Sun Cho South Korea Jung‐Sun Cho's profile →
Citations per field
00.5×3.8×
Jung‐Sun Cho · 1×
Citations per year

Countries citing papers authored by Guoxing Xu

Since Specialization
Citations

This map shows the geographic impact of Guoxing Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guoxing Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guoxing Xu more than expected).

Fields of papers citing papers by Guoxing Xu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Guoxing Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guoxing Xu. The network helps show where Guoxing Xu may publish in the future.

Co-authorship network of co-authors of Guoxing Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Guoxing Xu. A scholar is included among the top collaborators of Guoxing Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Guoxing Xu. Guoxing Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 2
2 23
3 5
4 4
5 9
6 3
7 27
8 7
9 5
10 13
11 9
12 19
13 1
14 67
15 10
16 8
17 48
18 70
19
[Effect of Lycium barbarum polysaccharides on the retinal ultrastructure of streptozocin-induced diabetic rats].
7
20 1

About Guoxing Xu

Guoxing Xu is a scholar working on Cancer Research, Ophthalmology and Oncology, having authored 28 papers that have together received 481 indexed citations. Recurring topics across this work include Pluripotent Stem Cells Research (5 papers), Cancer Cells and Metastasis (3 papers) and CRISPR and Genetic Engineering (3 papers). The work is most often cited by research in Orthopedics and Sports Medicine (50 citations), Cancer Research (76 citations) and Molecular Biology (304 citations). Guoxing Xu has collaborated with scholars based in China, Germany and United States. Frequent co-authors include Azra Fatima, Tomo Šarić, Zhengjie Huang, Qi Luo, Alexey Kuzmenkin, Haibin Wang, Kurt Pfannkuche, Borong Chen, Fengmei Chen and Dawei Jiang. Their work appears in journals such as PLoS ONE, The FASEB Journal and Biochemical and Biophysical Research Communications.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026